Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$43.91 USD
+0.39 (0.90%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $43.88 -0.03 (-0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 259 | 178 | 139 | 110 | 90 |
Receivables | 115 | 89 | 79 | 66 | 46 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 106 | 104 | 93 | 97 | 111 |
Other Current Assets | 9 | 8 | 7 | 7 | 10 |
Total Current Assets | 490 | 378 | 318 | 280 | 255 |
Net Property & Equipment | 283 | 238 | 244 | 260 | 234 |
Investments & Advances | 15 | 2 | 4 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 53 | 39 | 22 | 25 | 26 |
Intangibles | 613 | 37 | 39 | 41 | 41 |
Deposits & Other Assets | 26 | 21 | 17 | 5 | 11 |
Total Assets | 1,513 | 742 | 672 | 631 | 587 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 93 | 84 | 90 | 96 | 77 |
Current Portion Long-Term Debt | 0 | 3 | 2 | 12 | 8 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 126 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 2 | 5 | 9 | 1 | 2 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 225 | 95 | 104 | 112 | 90 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 590 | 73 | 75 | 34 | 39 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 22 | 22 | 18 | 13 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 873 | 213 | 226 | 183 | 159 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 486 | 455 | 422 | 410 | 367 |
Retained Earnings | 409 | 272 | 180 | 118 | 116 |
Other Equity | -8 | -9 | -7 | 43 | 41 |
Treasury Stock | 247 | 190 | 150 | 122 | 98 |
Total Shareholder's Equity | 639 | 529 | 446 | 449 | 428 |
Total Liabilities & Shareholder's Equity | 1,513 | 742 | 672 | 631 | 587 |
Total Common Equity | 639 | 529 | 446 | 449 | 428 |
Shares Outstanding | 47.90 | 48.30 | 47.80 | 47.50 | 46.90 |
Book Value Per Share | 13.35 | 10.95 | 9.32 | 9.45 | 9.12 |
Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 259 | 306 | 168 | 195 | 178 |
Receivables | 115 | 121 | 106 | 101 | 89 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 106 | 110 | 105 | 104 | 104 |
Other Current Assets | 9 | 6 | 6 | 7 | 8 |
Total Current Assets | 490 | 543 | 385 | 408 | 378 |
Net Property & Equipment | 283 | 281 | 279 | 243 | 238 |
Investments & Advances | 15 | 2 | 1 | 2 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 53 | 41 | 41 | 39 | 39 |
Intangibles | 613 | 619 | 626 | 37 | 37 |
Deposits & Other Assets | 26 | 25 | 20 | 19 | 21 |
Total Assets | 1,513 | 1,545 | 1,378 | 774 | 742 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 93 | 223 | 218 | 89 | 84 |
Current Portion Long-Term Debt | 0 | 0 | 13 | 2 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 126 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 2 | 31 | 18 | 12 | 5 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 225 | 258 | 251 | 106 | 95 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 590 | 638 | 488 | 73 | 73 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 25 | 22 | 22 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 873 | 949 | 789 | 225 | 213 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 486 | 478 | 471 | 457 | 455 |
Retained Earnings | 409 | 373 | 324 | 298 | 272 |
Other Equity | -8 | -8 | -8 | -8 | -9 |
Treasury Stock | 247 | 247 | 197 | 198 | 190 |
Total Shareholder's Equity | 639 | 595 | 589 | 549 | 529 |
Total Liabilities & Shareholder's Equity | 1,513 | 1,545 | 1,378 | 774 | 742 |
Total Common Equity | 639 | 595 | 589 | 549 | 529 |
Shares Outstanding | 47.90 | 48.20 | 48.20 | 48.10 | 48.30 |
Book Value Per Share | 13.35 | 12.35 | 12.22 | 11.40 | 10.95 |